How can pharmacists approach the ‘grey area’ surrounding PD-L1 testing?

How can pharmacists approach the ‘grey area’ surrounding PD-L1 testing?

VJOncology

1 year
340 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Jacob Kettle, PharmD, BCOP, of the University of Missouri Health Care, Columbia, MO, discusses the different ways in which pharmacists can overcome the uncertainties surrounding new tools, such as PD-L1 testing. Pharmacists are encouraged to be aware of the correct applications of these tools by identifying the patients who are most likely to benefit from them, as well as the limitations of each test. This interview was filmed at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference held in Denver, CO.
Up Next Autoplay
Human Immune Monitoring Center in Mount Sinai to Analyze the Efficacy of a New Drug for Cancer Therapy
Human Immune Monitoring Center in Mount Sinai to Analyze the Efficacy of a New Drug for Cancer Therapy
Category: General
2 Views
Mount Sinai Health System 2 weeks
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Category: General
20 Views
Cancer-News 1 month
Interesting Data Presented at WCLC 2019
Interesting Data Presented at WCLC 2019
Category: General
13 Views
Cancer-News 2 months
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
Category: General
20 Views
Cancer-News 2 months
The iQ Group Global acquires new anticancer drug platform from University of Texas
The iQ Group Global acquires new anticancer drug platform from University of Texas
Category: General
12 Views
Cancer-News 2 months
Clinical insights for hematological malignancies from an artificial intelligence decision-support tool.
Clinical insights for hematological malignancies from an artificial intelligence decision-support tool.
Category: General
118 Views
Annual-Meeting 5 months
Grandma Shout-Out: Very Grateful For Everything...Maybe Not All The Cooking
Grandma Shout-Out: Very Grateful For Everything...Maybe Not All The Cooking
Category: General
26 Views
Annual-Meeting 5 months
Questions About Larotrectinib: Who Should Be Tested, How Long Should They Be Treated, What Agent To Use
Questions About Larotrectinib: Who Should Be Tested, How Long Should They Be Treated, What Agent To Use
Category: General
48 Views
Annual-Meeting 5 months
Larotrectinib Efficacy & Safety In Pediatric TRK Fusion Cancer Patients: 94% Of The Children Treated With Larotrectinib Achieved A Response
Larotrectinib Efficacy & Safety In Pediatric TRK Fusion Cancer Patients: 94% Of The Children Treated With Larotrectinib Achieved A Response
Category: General
76 Views
Annual-Meeting 5 months
How To Identify Patients With An NTRK Gene Fusion: Will Require A Very Broad Genomic Sequencing
How To Identify Patients With An NTRK Gene Fusion: Will Require A Very Broad Genomic Sequencing
Category: General
301 Views
Annual-Meeting 5 months